Fb2 Individual Risk Assessment for Patients with Hematological Malignancies: A Basis for Optimized Treatment Strategies ePub
by M. Hallek
|Category:||Medicine and Health Sciences|
|Publisher:||Thieme Publishing Group (August 1, 1999)|
|Fb2 eBook:||1452 kb|
|ePub eBook:||1266 kb|
|Digital formats:||docx txt txt docx|
Goodreads helps you keep track of books you want to read.
Goodreads helps you keep track of books you want to read. Start by marking Individual Risk Assesment for Patients with Hematological Malignancies: A Basis for Optimized Treatment Strategies as Want to Read: Want to Read savin. ant to Read. Details (if other): Cancel. Thanks for telling us about the problem.
Patients with hematological malignancies represent only . 8% of all patients undergoing cardiac surgery
Patients with hematological malignancies represent only . 8% of all patients undergoing cardiac surgery. The literature of cardiac surgical procedures in this subset of patients is limited to only a few retrospective case series. Candidate patients for cardiac surgery procedures with a history of malignancies and antitumour therapy or with an active cancer and on antineoplastic treatment are increasingly common in daily practice. Oncological therapy can lead to cardiovascular injury and, therefore, has the potential for impacting operative risks and surgical strategies.
In adult patients with non-myeloid hematological malignancies who are . ESA treatment continues to be recommended for patients with low-risk myelodysplasia for similar reasons.
In adult patients with non-myeloid hematological malignancies who are at risk for. developing anemia during the course, and therapy of their illness, does the use of erythropoietic. judgment in the context of individual clinical circumstances or seek out the supervision of a qualified. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding. There is no evidence showing increased survival as a result of ESA treatment.
Are you sure you want to remove Individual Risk Assessment for Patients with . by M. Hallek, Emmerich, Nowrousian. Published August 26, 1999 by Thieme Publishing Group There's no description for this book yet.
Are you sure you want to remove Individual Risk Assessment for Patients with Haematological Malignancies from your list? Individual Risk Assessment for Patients with Haematological Malignancies. Published August 26, 1999 by Thieme Publishing Group. Therapy, Health risk assessment, Risk Assessment, Diseases, Hematologic Neoplasms, Blood.
In hematological malignancies such as MM, acute myelogenous .
In hematological malignancies such as MM, acute myelogenous leukemia (AML), and acute lymphoblastic leukemia (ALL), a correlation was found between clinical responses to cytotoxic chemotherapy and mitochondria priming state prior to treatment; better responses to treatment were observed for patients’ cells with higher pretreatment mitochondrial propensity to undergo apoptosis Although treatment with ABT-737 induces massive apoptosis in multiple tumor cell .
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells. Cytotoxic T lymphocytes (CTLs) play a central role in antitumor immunity; unfortunately, nonspecific approaches for targeted recognition of tumor cells by CTLs to mediate tumor immune evasion in hematological malignancies imply multiple mechanisms, which may or may not be clinically relevant.
The major reason for treatment failure in acute leukemia (AL) is the . In conclusion, this study provides the basis for rational and efficient molecular quantitative determination of MRD levels.
The major reason for treatment failure in acute leukemia (AL) is the resistance of leukemic blasts to chemotherapeutic agents, which is accompanied by an inability of the immune system to eradicate residual leukemic cells surviving initial treatment.
An objective, weighted risk score for IMD can accurately discriminate patients with hematological malignancies at low risk for developing .
An objective, weighted risk score for IMD can accurately discriminate patients with hematological malignancies at low risk for developing mold disease, and could possibly facilitate screening-out of low risk patients less likely to benefit from intensive diagnostic monitoring or mold-directed antifungal prophylaxis. Similar to the retrospective cohort, risk scores for patients studied during 2009-2012 were well calibrated with the incidence rate of IMD within 90 days of hospital admission (Figure 1). A score of less than 6 was also confirmed as the optimal cut-off for discriminating low-risk patients in the prospective study cohort, with an aROC of . 4.
Obinutuzumab is being developed for the treatment of various hematological malignancies. This application was seeking approval for obinutuzumab in combination with chlorambucil for previously untreated patients with CLL. CHMP assessment report. The sponsor applied for the following indication: Gazyvaro in combination with chlorambucil is indicated for the treatment of patients with previously untreated CLL.
Patients with CLL, MM receiving treatment in the majority of cases in the general wards, where the risk of infection . Therefore, against the background of agranulocytosis fever (febrile 141 neutropenia) is the basis for the appointment of broad spectrum antibiotics.
Second, it is Leukemia CLL, in which there is a pronounced secondary immunodeficiency, even in the absence of tumor progression of the process. With modern antibacterial drugs, granulocyte colony-stimulating factor and other adjuvant therapy, the prognosis of infectious complications of neutropenia Leukemia in most cases favorable.